achievements company in numbers
0
years on the market
0
branches
(in 24 regions)
0
regular customers
0
delivery points
0
product names
0
suppliers
0
total warehouse area
0
orders per day
interesting news
Glory to Ukraine!
Actual Recommended
The "KEY OF HOPE" program is aimed at increasing the awareness of patients about the disease and reducing the cost of therapy for the patient with drugs included in the Program, intended for the treatment of certain types of oncological diseases by influencing the immune system;
Preparation of the project:
KITRUDA® (pembrolizumab)
Keytruda conc. d/r-nu d/inf. 25 mg/ml fl. 4 ml No. 1
The promotion is held until: 31.12.2025
You can learn more about the terms of participation in the project on the website: https://medicard.com.ua/medicard/page/key_hope_ruless/
The "Asakard" program was developed by the Biocodex company in order to ease your burden during the long-term treatment of intestinal diseases.
Drugs:
ASAKOL® coated tablets, enteric-soluble 800 mg No. 60;
ASAKOL® coated tablets, enteric-soluble 400 mg No. 100;
ASAKOL® rectal suppositories of 500 mg No. 20.
You can learn more about the terms of participation in the project on the website:https://privit.com.ua/asacard/
"CHERVONA KALINA"
The goal of the Program is to improve access of Ukrainian patients to effective innovative treatment with medicines included in the Program.
The program is valid from October 1, 2023 to March 31, 2028 inclusive.
The patient support program "CHERVONA KALYNA" is implemented by Astellas Pharma LLC with information and technical support from Medicard LLC
More information about the conditions for participation in the project can be found on the project website.
The patient support program aims to make treatment of patients with heart failure with reduced ejection fraction more accessible
The program "PATH TO A HEALTHY HEART" is implemented on the initiative of PJSC "PHARMACEUTICAL COMPANY "DARNYTSYA" with the technical support of LLC "MEDYCARD PLUS"
More details about the terms of participation in the project can be found on the project website
AFFORDABLE PROTECTION OF THE LIVER AND GALLBLADDER
The hepatobiliary system includes the liver, gallbladder, intrahepatic and extrahepatic bile ducts. Functional disorders of the hepatobiliary system occupy a significant place among diseases of the gastrointestinal tract. Pathologies associated with the formation and secretion of bile are especially common.
High-quality treatment of disorders of the hepatobiliary system increases the chances of a full recovery and prevents the appearance of complications.
If your doctor has prescribed you a medicine that is part of the "AFFORDABLE PROTECTION OF THE LIVER AND GALLBLADDER" program, you can become its participant and receive medicines included in the Program at a discount at partner pharmacies.
The social patient support program aims to increase awareness and accessibility of therapies for the treatment of patients with joint pain.
Information can be found on the website https://medicard.com.ua/medicard/page/movement_wo_pain/
Take control of your blood pressure
The social patient support program aims to make quality antihypertensive therapy more accessible.
Information can be found on the website https://medicard.com.ua/medicard/page/control_your_pressure/
Suppliers global partnership
Darnitsa is a pharmaceutical company, a leader in Ukrainian market in the production and physical sales of prescription (Rx) and over-the-counter (OTC) generic products. The company began operating in 1930. In 2019, Darnitsa rebranded and announced a new business strategy: to transform based on digital technologies, to build an international brand and to lead in the generic segment of medicines.
The company's portfolio includes 280 names of ready-to-use drugs. Darnitsa focuses on the treatment of cardiac, neurological diseases and pain. Its products are exported to 16 countries.
The Darnitsa plant in Kyiv has 14 production lines certified according to the GMP standard.
Farmak is the leader of pharmaceutical market with a share of 5.9 %. The medicines of all fourteen therapeutic groups are produced at the factory. Among the main areas are anti-cold, endocrinological, gastroenterological, cardiological and neurological portfolios. Every year, Farmak launches approximately 20 new drugs on the market; these are complex modern medications needed by millions of people, both in our country and abroad. About a hundred drugs are currently under development.
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology, respiratory diseases.
Orion's main market is Finland, where it is the clear market leader. Orion’s products are marketed in over a hundred countries, and the Group's own human pharmaceuticals sales organization covers almost all key European markets and a few Southeast Asian countries. In other markets Orion’s products are sold by several collaboration partners. All of Orion's manufacturing plants and most of its R&D operations are in Finland. Orion’s headquarters are in Espoo.
«Perrigo is a world leading health company which creates and provides non-prescription (ОТС) and perscription (Rx) medicines, consumer goods, food products and active pharmaceutical ingredients (API). Since 1887, Perrigo has been providing its customers and consumers with high-quality products that support personal health and wellness by delivering effective solutions that meet the needs of consumers almost all over the world – mostly in Northern America, Europe, Australia, and other key markets like Israel and China».
the Company RECORDED GROUPS, with headquarters in Milan (Italy), has offices in many countries of Central and Eastern Europe, in Russia, in Turkey, in North Africa and in the United States of America.
